West Pharmaceutical Services, Inc. — Q1 2022 Form 10-Q Summary
Business Context and Reporting Period
West Pharmaceutical Services, Inc. is a global manufacturer of containment, packaging, drug-delivery and contract-manufacturing products serving biologic, generic, pharmaceutical, diagnostic and medical-device customers. The filing covers the unaudited three months ended March 31, 2022, compared with the three months ended March 31, 2021.
The company reports two segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products represented $601.3 million of sales, or approximately 83% of consolidated sales; Contract-Manufactured Products represented $118.7 million.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $720.0 million | $670.7 million | 7.4% increase; 11.0% increase excluding currency |
| Gross profit | $284.6 million | $271.9 million | 4.7% increase |
| Gross margin | 39.5% | 40.5% | Down 1.0 percentage point |
| Operating profit | $189.7 million | $175.6 million | 8.0% increase |
| Operating margin | 26.3% | 26.2% | Up 0.1 percentage point |
| Adjusted operating profit | $189.9 million | $179.2 million | 6.0% increase |
| Adjusted operating margin | 26.4% | 26.7% | Down 0.3 percentage point |
| Net income | $173.8 million | $151.2 million | 14.9% increase |
| Diluted EPS | $2.29 | $1.99 | 15.1% increase |
| Cash flow from operations | $151.2 million | $88.7 million | Increase of $62.5 million |
| Capital expenditures | $65.8 million | $54.7 million | Increase of $11.1 million |
Research and development expense increased 19.7% to $14.6 million, while SG&A increased 4.0% to $83.4 million. The effective tax rate declined to 11.3% from 16.4%, primarily due to a $5.9 million state tax valuation allowance reversal. Equity in net income of affiliated companies increased to $7.2 million from $5.0 million.
Liquidity, Debt and Capital Allocation
- Cash and cash equivalents were $667.7 million at March 31, 2022, down from $762.6 million at December 31, 2021.
- Working capital was $1,105.7 million, compared with $1,147.9 million at year-end 2021. Inventories increased to $416.5 million from $378.4 million.
- Total debt was $252.5 million, including $44.2 million classified as current and $208.3 million classified as long-term.
- The company amended and extended its revolving credit facility in March 2022, increasing capacity from $300.0 million to $500.0 million and extending maturity to March 2027. Available capacity, including outstanding letters of credit, was $497.6 million; there were no revolver borrowings.
- The company was in compliance with its debt covenants. Management stated that cash on hand, operating cash flow and credit-facility availability should meet foreseeable liquidity needs.
- Financing cash outflows included $147.1 million for repurchases under the 2022 program, $18.8 million for employee tax-withholding share repurchases and $13.4 million of dividends.
- During the quarter, the company repurchased 390,000 shares at an average price of $377.23 per share. The authorization allowed repurchases of up to 650,000 shares, leaving 260,000 shares authorized at March 31, 2022.
Material Changes Versus the Prior Comparable Period
- Reported sales growth was reduced by a $24.2 million unfavorable foreign-currency translation effect. Organic sales increased 14.4% in Proprietary Products and declined 3.8% in Contract-Manufactured Products.
- Proprietary Products benefited from growth in high-value offerings, including NovaPure and Westar products, but the comparison included approximately $15 million of one-time COVID supply-agreement fees recognized in Q1 2021.
- Contract-Manufactured Products sales declined primarily because of lower diagnostic-device component sales, partly offset by price increases.
- Consolidated gross margin declined because of inflation-driven transportation, compensation and other overhead costs and the absence of the prior-year COVID-related fees. Contract-Manufactured Products margin improved due to price increases and production efficiencies.
- Operating profit benefited from higher sales, improved segment performance, a $2.8 million gain on oil hedges versus a $0.5 million loss in Q1 2021, and the absence of Q1 2021 restructuring charges and a $2.2 million cost-investment impairment.
- Comprehensive income increased to $151.0 million from $121.6 million, although foreign-currency translation generated a $22.1 million loss in Q1 2022.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide a clear numerical full-year sales, earnings or cash-flow guidance range. Management stated that liquidity remains strong and that it expects available cash resources and credit capacity to support foreseeable needs.
- COVID-19 had limited the company’s operations during the quarter, but management noted continuing uncertainty regarding employee health, suppliers, transportation, customers and future government actions.
- Key risks include demand volatility, customer inventory changes, supply-chain interruptions, inflation and petroleum-based raw-material costs, labor availability, foreign-exchange movements, competition, regulatory approval and commercialization of customer products, and reliance on certain suppliers and affiliates.
- The company maintains crude-oil call options to hedge exposure to elastomer-related surcharges. At March 31, 2022, contracts covered 154,320 barrels through June 2023 at a weighted-average strike price of $76.06 per barrel.
- Other unusual Q1 2022 items included the $5.9 million tax valuation allowance reversal, a $2.8 million oil-hedge gain, $0.8 million of contingent-consideration expense and a $0.6 million pension settlement charge.
- The 2020 restructuring plan recorded no new charges during the quarter; $2.9 million of related obligations remained at March 31, 2022.
- Management reported no material changes to previously disclosed legal proceedings or risk factors, and no material off-balance-sheet financing arrangements other than ordinary-course purchase obligations and letters of credit.
Important Facts for Investors to Verify
- Whether Proprietary Products growth and high-value product demand offset the absence of prior-year COVID-related fees.
- Whether pricing actions and productivity improvements can offset inflation, labor costs, transportation costs and raw-material pressures.
- The sustainability of the 11.3% effective tax rate, given that Q1 benefited from a discrete state tax valuation allowance reversal.
- Progress on capital expenditures, inventory buildup and operating-cash-flow conversion.
- Use of the expanded $500.0 million revolving credit facility and the July 2022 maturity of the $42.0 million Series A notes.
- Foreign-currency effects, supply-chain conditions, customer demand and the performance of diagnostic-device components.
- The company’s completion of the remaining 260,000 authorized share repurchases by December 31, 2022.